Reykjalundur Rehabilitation Center
Mosfellsbaer, 270, Iceland
NCT Number: NCT01391741
People with disease (PD) tend to walk with short steps, decreased velocity, and increased stride time variability. Short steps and increased variability are related to greater fall risk. In addition, concurrent performance of a cognitive task (dual-task (DT)) has marked effects on gait in people with PD which is considered to reflect an impaired automaticity of gait.
Objective: To investigate short and long term effects of high-volume walking with visual spatial cues (VSC) on gait variables, automaticity, and functional mobility, in people with Parkinson´s Disease (PD), compared with walking without VSC.
Looking for future studies?
Notify MeUp to 79 year
All sexes
Interventional
Phase 3
Mosfellsbaer, 270, Iceland
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Walking with visual cues for 30 minutes, 4 times a week for 4 weeks
Walking without visual cues, but verbal encouragement twice a week to take longer steps, for 30 minutes, 4
Time frame: Before, after and 3 months after a 4 week training period
Time frame: Before, after and 3 months after a 4 week training period
Time frame: Before, after and 3 months after a 4 week training period
Time frame: Before, after and 3 months after a 4 week training period
University of Iceland
Other
The Effect of High-Volume Walking With Visual Cues on Gait in People With Parkinson´s Disease. A Randomized Controlled Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03866603
Basal Ganglia Diseases, Brain Diseases
Tucson, Arizona, United States
View Trial DetailsNCT01038310
Basal Ganglia Diseases, Brain Diseases
Homburg/Saar, Saarland, Germany
View Trial DetailsNCT03103919
Basal Ganglia Diseases, Brain Diseases
Fountain Valley, California, United States
View Trial DetailsNCT01960985
Basal Ganglia Diseases, Brain Diseases
São Paulo, Brazil
View Trial Details